IL2 and systemic lupus erythematosus: In addition to this, it was shown that Tfh cells are expanded in SLE patients (43, 44), providing a complementary rationale for low-dose IL-2 therapy in order to inhibit the differentiation and expansion of T cells, which are required for the generation of autoantibody secreting B and plasma cells (13, 44, 45).